Zacks Research upgraded shares of Ono Pharmaceutical (OTCMKTS:OPHLF – Free Report) from a hold rating to a strong-buy rating in a report issued on Monday morning,Zacks.com reports.
Ono Pharmaceutical Stock Up 4.4%
OPHLF stock opened at $15.56 on Monday. The business’s 50-day moving average price is $14.40 and its 200-day moving average price is $14.67. The stock has a market cap of $7.31 billion, a P/E ratio of 15.72 and a beta of 0.34. The company has a quick ratio of 2.56, a current ratio of 3.02 and a debt-to-equity ratio of 0.10. Ono Pharmaceutical has a twelve month low of $10.06 and a twelve month high of $18.67.
Ono Pharmaceutical Company Profile
Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.
One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.
Further Reading
- Five stocks we like better than Ono Pharmaceutical
- Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet
- 3 Overlooked Energy ETFs Delivering Strong Returns and Income
- 3 Space Stocks That Could Outshine SpaceX After Its IPO
- JPMorgan’s Q2 Strength Gives the Stock Rally New Support
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
